Point72 Asia Singapore Pte. Ltd. Sells 21,090 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Point72 Asia Singapore Pte. Ltd. lessened its position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) by 30.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 47,073 shares of the company’s stock after selling 21,090 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Protalix BioTherapeutics were worth $48,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of Protalix BioTherapeutics in the 2nd quarter valued at about $37,000. GSA Capital Partners LLP boosted its stake in Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Protalix BioTherapeutics during the 2nd quarter worth $67,000. Ground Swell Capital LLC bought a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at $73,000. Finally, Squarepoint Ops LLC lifted its stake in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after purchasing an additional 119,949 shares during the period. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Protalix BioTherapeutics Price Performance

Shares of PLX stock opened at $1.69 on Friday. The stock has a market cap of $124.43 million, a PE ratio of -13.00 and a beta of 0.74. The stock has a 50-day moving average of $1.29 and a 200-day moving average of $1.16. Protalix BioTherapeutics, Inc. has a one year low of $0.82 and a one year high of $1.90.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Protalix BioTherapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.